Nathan D. Jorgensen sold $37k of VYGR
Chief Financial Officer at Voyager Therapeutics, Inc.. 7,666 shares at an average of $4.78, traded Oct 3, 2025, filed Oct 7, 2025.
Score components
- +22RoleCFO
- +6Trade size$37k at market
- 0Share of holdings soldSold 5.8% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -10.8%, 3m -15.0%, 6m -16.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-25-097522, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 3, 2025 | SOpen-market sale Common Stock10b5-1 | -7,666 | $4.78 | $37k | 123,834 | Oct 7, 2025 |
Related signals
Other insiders at Voyager Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 11Weak | Voyager Therapeutics, Inc. | Alfred Sandrock President and CEO | $45k 11,511 shares | -2% | |
| 10Weak | Voyager Therapeutics, Inc. | Todd Alfred Carter Chief Scientific Officer | $16k 4,174 shares | -3% | |
| 17Weak | Voyager Therapeutics, Inc. | Nathan D. Jorgensen Chief Financial Officer | $18k 4,668 shares | -3% | |
| 27Weak | Voyager Therapeutics, Inc. | Alfred Sandrock President and CEO | $54k 14,197 shares | -3% | |
| 15Weak | Voyager Therapeutics, Inc. | Robin Swartz COO & CBO | $24k 6,458 shares | -3% | |
| 10Weak | Voyager Therapeutics, Inc. | Todd Alfred Carter Chief Scientific Officer | $11k 3,301 shares | -2% | |
| 26Weak | Voyager Therapeutics, Inc. | Alfred Sandrock President and CEO | $40k 11,732 shares | -2% | |
| 15Weak | Voyager Therapeutics, Inc. | Robin Swartz COO & CBO | $13k 3,882 shares | -2% | |
| 30Weak | Voyager Therapeutics, Inc. | Todd Alfred Carter Chief Scientific Officer | $14k 3,525 shares | -2% | |
| 46Moderate | Voyager Therapeutics, Inc. | Alfred Sandrock President and CEO | $46k 12,192 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.